Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma to present clinical trial poster at Madrid oncology meeting as administration continues

Redx’s shares remain suspended on AIM as it continues to be under administration, although an exit is expected in the future after the firm struck a deal at the end of July to sell its Bruton’s tyrosine kinase programme for US$40mln
Cancer tests
The life sciences group entered administration in May when Liverpool Council called in a £2mln loan

Redx Pharma PLC (LON:REDX) has announced it will present a poster on their planned first-in-human clinical trial for its RXC004 colorectal cancer treatment at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid on September 9.

The positive news comes with Redx’s shares remaining suspended on AIM as it continues to be under administration, although an exit is expected in the future after the firm struck a deal at the end of July to sell its Bruton’s tyrosine kinase (BTK) inhibitor technology and drug development programme for US$40mln.

READ: Redx Pharma shares suspended as Liverpool City Council calls in loan

The life sciences group’s shares were suspended in May after it entered into administration when Liverpool Council called in a £2mln loan.

FRP Advisory, RedX’s administrator revealed on August 10 that it had contemplated a fund raise to pay off Liverpool Council.

As there was no precedent for the raising of funds on AIM by a company in administration, this required detailed analysis of the legal structuring and in-depth discussions with the biotech's brokers and advisers, FRP Advisory added.

In the event, FRP said, one large shareholder vetoed the plan and the administrator subsequently sold the BTK inhibitors business to US firm Loxo.

READ: Administrators of Redx Pharma mulled fund raise to pay off Liverpool Council

BTK was to be one of the second-generation of compounds with fewer side-effects than the market leader Imbruvica (often referred to as Ibrutinib).

The next steps out of administration are for FRP to be satisfied that Redx can continue as a going concern, following which control will be handed back to the directors who are expected at that point to apply for trading on AIM to resume again.

The process is expected to be take up to 12 weeks.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
Picture of drugs
July 18 2017
Gross profit in the half year to December was up by 34%
clinical-trial.jpg
June 30 2017
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use